Search
SOLACI Congress
HomePharmacologyAntithrombotic Anticoagulants

Antithrombotic Anticoagulants

View Category

Antithrombotic Anticoagulants

Do NOACs Result in Any Benefit in TAVR?

Courtesy of Dr. Carlos Fava. The need for anticoagulation after transcatheter aortic valve replacement (TAVR) is over 15%...
solaci -
Learn More
Antithrombotic Anticoagulants

PCI and Anticoagulation: What is the best strategy?

Most patients with atrial fibrillation require anticoagulation to reduce the risk of stroke or systemic embolization. Today,...
solaci -
Learn More
Antithrombotic Anticoagulants

Antithrombotic Strategies in Atrial Fibrillation and Angioplasty

What is the most appropriate antithrombotic strategy for a patient with atrial fibrillation and coronary artery disease,...
solaci -
Learn More
Antithrombotic Anticoagulants

Safety of Combining New Anticoagulant Agents and Dual Antiplatelet Therapy

Atrial fibrillation is the most common arrhythmia and its combination with a history of acute myocardial infarction...
solaci -
Learn More
Antithrombotic Anticoagulants

New Anticoagulant Agents in Atrial Fibrillation in Latin American Patients, Specifically

There is limited information on the use of antithrombotic therapies and their outcomes in Latin American patients...
solaci -
Learn More
Antithrombotic Anticoagulants

Galileo: Rivaroxaban After TAVR Stopped Due to Early Event Rates

Patients undergoing transcatheter aortic valve replacement (TAVR) randomized to rivaroxaban in the GALILEO trial experienced higher risk...
solaci -
Learn More
Antithrombotic Anticoagulants

TCT 2018 | OAC-ALONE: Anticoagulation Alone 1 Year After Stenting in Patients with Atrial Fibrillation

Up to now, there had been no randomized controlled trial assessing oral anticoagulation alone vs. oral anticoagulation...
solaci -
Learn More
Acute coronary syndromes

ESC 2018 | MATRIX: 1-Year Superiority of Transradial Access

Transradial access should be the access of choice in patients with acute coronary syndrome, while bivalirudin has...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

Dr. Omar Tupayachi - 0
While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Dr. Andrés Rodríguez - 0
Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Dr. Omar Tupayachi - 0
Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Institutional News

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy